10-K: Cabaletta Bio Advances Autoimmune CAR T, Faces Funding Doubt

Cabaletta Bio progresses its lead CAR T therapy, rese-cel, into registrational trials for autoimmune diseases while reporting significant losses and a need for further funding.

Summary

• Cabaletta Bio is a late clinical-stage biotechnology company developing engineered T cell therapies (CARTA platform) for autoimmune diseases.
• Rese-cel (formerly CABA-201), a CD19-CAR T construct, is the lead product candidate, designed for transient and deep B cell depletion to reset the immune system.
• A registrational trial for rese-cel in dermatomyositis (DM) or anti-synthetase syndrome (ASyS) was initiated in December 2025, targeting approximately 16,000 to 20,000 eligible patients in the U.S. with DM/ASyS.
• Ongoing Phase 1/2 trials are evaluating rese-cel in systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and generalized myasthenia gravis (gMG) with standard preconditioning.
• Early data from a Phase 1/2 trial evaluating rese-cel without preconditioning in pemphigus vulgaris (PV) patients showed substantial B cell depletion and rapid reduction in autoantibodies.
• The company announced IND clearance in January 2026 for rese-cel manufactured using Cellares' automated Cell Shuttle platform, aiming for scalability to thousands of patients per year.
• Cabaletta Bio reported a net loss of $167.9 million for the year ended December 31, 2025, compared to $115.9 million in 2024, with an accumulated deficit of $517.0 million.
• Cash, cash equivalents, and investments totaled $133.6 million as of December 31, 2025, expected to fund operations into the fourth quarter of 2026.
• The company has identified conditions that raise substantial doubt about its ability to continue as a going concern beyond the fourth quarter of 2026 without additional funding.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing with mixed sentiment. While significant clinical progress and regulatory designations for rese-cel are positive, the substantial and increasing net losses, accumulated deficit, and explicit 'going concern' warning indicate significant financial instability and high future funding risk.

Positives

• Rese-cel has received multiple FDA designations: Fast Track for dermatomyositis, SLE, lupus nephritis, systemic sclerosis, and multiple sclerosis; Orphan Drug for myositis and systemic sclerosis; Rare Pediatric Disease for juvenile dermatomyositis; and Regenerative Medicine Advanced Therapy (RMAT) for myositis, SLE, LN, and systemic sclerosis.
• Initiation of a registrational cohort for rese-cel in dermatomyositis/anti-synthetase syndrome in December 2025, based on promising Phase 1/2 data showing major Total Improvement Score (TIS) responses with no immunomodulators.
• Rese-cel demonstrated a favorable safety profile in initial trials, with 95% of 40 patients experiencing no or Grade 1 Cytokine Release Syndrome (CRS) and 95% experiencing no Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS).
• The protocol for the myositis registrational trial permits outpatient administration, potentially reducing hospital resource utilization and improving reimbursement.
• Successful IND clearance in January 2026 for rese-cel manufactured using Cellares' automated Cell Shuttle platform, offering potential for scalability to thousands of patients per year with minimal capital investment.
• Early clinical data from the RESET-PV trial without preconditioning showed substantial B cell depletion and rapid autoantibody reduction in two of three patients, suggesting potential for market expansion and improved patient experience.

Negatives

• Cabaletta Bio has incurred significant net losses since inception, with a net loss of $167.9 million in 2025 and $115.9 million in 2024.
• The company has an accumulated deficit of $517.0 million as of December 31, 2025.
• There is substantial doubt about the company's ability to continue as a going concern beyond the fourth quarter of 2026 without securing additional funding.
• The company is highly dependent on third-party manufacturers (Minaris, Lonza, Cellares) for its manufacturing needs, which introduces risks of delays, capacity issues, and compliance failures.
• Clinical trials for cellular therapies are complex and may be associated with serious adverse events like ICANS and CRS, which could impact regulatory approval and commercial potential.
• The registrational trials may rely on a single-arm design with external controls, which could be subject to heightened FDA scrutiny regarding potential bias and reliability, potentially delaying or preventing approval.
• The market opportunities for product candidates may be limited to patients who have failed prior treatments, and the target patient populations are relatively small, creating uncertainty around long-term commercial viability and pricing.

Risks

• We are a clinical-stage company with a limited operating history, have incurred significant losses since our inception, and anticipate that we will continue to incur significant losses for the foreseeable future.
• We are highly dependent on our relationships with Minaris Advanced Therapies, LLC, Lonza Houston Inc., and/or Cellares Corporation for our current manufacturing needs, and manufacturing capacity reductions or delays could adversely impact trials.
• We are reliant on intellectual property licensed to us by Nanjing IASO Biotherapeutics Co., Ltd., and termination of this license agreement would result in the loss of significant rights.
• If we are unable to obtain and maintain sufficient intellectual property protection for our current product candidates and technologies or any future product candidates, we may not be able to compete effectively.
• We will need to raise substantial additional funding before we can expect to complete development of any of our product candidates or generate any revenues from product sales.
• If we encounter difficulties enrolling patients in our RESET clinical trials for rese-cel or future clinical trials, these clinical development activities could be delayed or otherwise adversely affected.
• If we are unable to advance our product candidates through clinical development, obtain regulatory approval and ultimately commercialize our product candidates, or experience significant delays in doing so, our business will be materially harmed.
• Results of earlier studies may not be predictive of future study or trial results, and we may fail to establish an adequate safety and efficacy profile to conduct clinical trials or obtain regulatory approval.
• If serious adverse events, undesirable side effects or unexpected characteristics are identified during the development of any of our product candidates, we may need to delay, abandon or limit further clinical development.
• Manufacturing and administering our product candidates is complex and we may encounter difficulties in technology transfer to a contract manufacturing organization.
• We may be unable to reach agreement with the FDA or comparable foreign regulatory authorities on the methodologies for, and assessment of, comparability of different versions of a product candidate.
• We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.
• We may establish our own manufacturing facility and infrastructure, which will be costly and time-consuming, and which may not be successful.
• Our future success depends in part upon our ability to retain our key employees, consultants and advisors and to attract, retain and motivate other qualified personnel.
• We have identified conditions that raise substantial doubt about our ability to continue as a going concern. If we are unable to secure additional funding beyond our current cash position that enables our operations into the fourth quarter of 2026, we may be forced to delay, reduce or discontinue our product development programs efforts or other operations.
• Cellular therapies are a novel approach, and negative perception or increased regulatory scrutiny (e.g., FDA investigation into T cell malignancies for CAR T therapies) could adversely affect business or approvals.
• Our registrational trials may rely on a single-arm design and an external control; if regulatory authorities determine that the external control is unsuitable, we may be unable to obtain approval on anticipated timelines, or at all.
• Product liability lawsuits could incur substantial liabilities and limit commercialization.
• Changes in patent law or interpretation could diminish the value of patents, impairing our ability to protect product candidates.
• If we are unable to protect the confidentiality of trade secrets, our business and competitive position would be harmed.
• The manufacture of viral vectors is complex and variable, with a limited number of manufacturers, posing supply risks.

Future Outlook

Cabaletta Bio anticipates BLA submission for rese-cel in myositis in 2027. Complete Phase 1/2 data for RESET-SLE, RESET-SSc, and RESET-MG trials are expected in the first half of 2026. Durability data from no-preconditioning SLE, LN, and PV patients, as well as patients treated with Cellares Cell Shuttle-manufactured rese-cel, are expected in the second half of 2026. The company plans to announce the registrational cohort design for SSc in the first half of 2026 and for MG in mid-2026. Existing cash, cash equivalents, and investments are expected to fund operations into the fourth quarter of 2026, but substantial additional financing will be required to complete clinical trials and commercialization.

Management Comments

• Management believes the CABA platform has the potential to safely enable complete and durable responses for a broad range of autoimmune diseases.
• Management believes rese-cel may have the potential to reset the immune system and transform treatment of a broad range of autoimmune diseases with high unmet need.
• Management is committed to advancing to optimize the patient experience through minimizing the requirement for inpatient stay, optimizing the preconditioning regimen, reducing the burden of apheresis, and/or innovating manufacturing to address scale in autoimmune disease.
• Management believes there is substantial doubt about the company's ability to continue as a going concern for at least twelve months following the filing of this Annual Report on Form 10-K, and will need to obtain additional funding.

Industry Context

StockSavvy.ai notes that Cabaletta Bio is operating in the rapidly evolving field of CAR T cell therapies, extending their application from oncology to autoimmune diseases. This represents a significant industry trend towards leveraging advanced cell engineering for a broader range of conditions. The company faces competition from established pharmaceutical and biotechnology firms, including those with existing CAR T oncology platforms (e.g., Novartis' Kymriah, Gilead's Yescarta) that are now exploring autoimmune applications. The regulatory landscape for CAR T in autoimmune diseases is still developing, making Cabaletta's progress and FDA interactions particularly noteworthy for setting precedents. The focus on automated manufacturing platforms like Cellares' Cell Shuttle aligns with industry efforts to improve scalability and cost-efficiency for cell therapies.

Comparison to Industry Standards

• Rese-cel's design, incorporating a 4-1BB co-stimulatory domain and CD3-zeta signaling domain, is noted to be highly similar to the construct used by Dr. Georg Schett in academic clinical studies published in Nature Medicine and Lancet Rheumatology, which demonstrated deep and durable clinical responses in SLE patients.
• The tolerability profile of Cabaletta's exclusively licensed fully human CD19 binder, clinically evaluated in a dual-CD19xCD22 CAR T candidate for B cell leukemia and lymphoma by IASO in China (approximately 20 patients), is considered favorable for autoimmune disease development, suggesting a comparable safety foundation to established oncology CAR T therapies.
• The observed 95% rate of no or Grade 1 CRS and 95% rate of no ICANS in the first 40 rese-cel patients with preconditioning compares favorably to the known severe side effect profiles, including life-threatening events, observed in some oncology CAR T therapies (e.g., Kymriah, Yescarta), indicating a potentially better safety profile for autoimmune applications.
• The company's strategy to use pooled safety data from across the RESET clinical trial program to supplement myositis-specific safety data for BLA submission, aiming for a safety database of approximately 100 autoimmune disease patients, is a pragmatic approach to meet regulatory requirements given the rarity of some target indications, similar to strategies seen in other rare disease drug development.

Management Changes

Corporate Governance

Legal Proceedings

• The company was subject to a securities class action lawsuit filed in February 2022, which was voluntarily dismissed by the plaintiff in October 2022.
• As of December 31, 2025, the company was not party to any material litigation or legal proceedings expected to have a material adverse impact on its financial position, results of operations, or cash flow.

Related Party Transactions

• The company has a license agreement with the Trustees of the University of Pennsylvania (Penn) and Children's Hospital of Philadelphia (CHOP), co-founded by Aimee Payne, M.D., Ph.D., and Michael Milone, M.D., Ph.D., who are scientific co-founders of Cabaletta Bio. This agreement involves annual license maintenance fees and potential milestone and royalty payments.
• The company has Master Translational Research Services Agreements with Penn for research, development, and manufacturing services, with expenses of $5.062 million in 2025 and $3.250 million in 2024.

Stakeholder Impact

• **Shareholders:** Face significant dilution risk from future equity offerings and warrant exercises. The 'going concern' doubt and recurring losses pose a substantial risk to investment value. Stock price volatility is expected due to clinical trial results and financial updates.
• **Patients:** Potential for deep, durable, and potentially curative responses for a broad range of autoimmune diseases with unmet medical needs, particularly with rese-cel. However, they also face risks of serious adverse events from novel cell therapies and potential delays in product availability.
• **Employees:** The company's ability to attract and retain highly qualified personnel is critical for its success, with stock options used as incentives. The 'going concern' warning could impact employee morale and retention.
• **Suppliers/Manufacturers (Minaris, Lonza, Cellares, Oxford, IASO):** The company's reliance on these third parties for manufacturing and intellectual property means their performance and stability directly impact Cabaletta's operations. Minaris's manufacturing agreement is set to expire in August 2026, requiring a transition.
• **Creditors:** The company's substantial losses and 'going concern' doubt increase credit risk, potentially making future debt financing more challenging or expensive.

Next Steps

• Complete Phase 1/2 data from RESET-SLE, RESET-SSc, and RESET-MG trials in the first half of 2026.
• Present initial clinical experience from patients treated with rese-cel manufactured by Cellares Cell Shuttle in the first half of 2026.
• Announce registrational cohort design for SSc in the first half of 2026.
• Announce registrational cohort design for MG in mid-2026.
• Present durability data from no-preconditioning SLE, LN, and PV patients, as well as Cellares Cell Shuttle-manufactured rese-cel patients, in the second half of 2026.
• Anticipate Biologics License Application (BLA) submission for myositis in 2027.
• Continue to seek additional funding through equity offerings, debt financings, or other capital sources to support operations beyond Q4 2026.

Key Dates

Recommendation

Cabaletta Bio presents a high-risk, high-reward investment profile. The clinical progress of rese-cel, particularly the initiation of a registrational trial for myositis and promising early data in other autoimmune indications, along with multiple FDA expedited designations, indicates strong therapeutic potential. The efforts to scale manufacturing through automation are also positive. However, the company's significant and increasing net losses, substantial accumulated deficit, and explicit 'going concern' warning highlight critical financial challenges and a clear need for additional capital. While the long-term potential is considerable if rese-cel achieves regulatory approval and commercial success, the near-term financial risks and uncertainties surrounding funding and clinical trial outcomes warrant a 'hold' recommendation for seasoned investors. A 'buy' would be premature given the financial instability, and a 'sell' would disregard the significant clinical upside and positive regulatory interactions.

Keywords

Cabaletta Bio, rese-cel, CAR T therapy, autoimmune disease, dermatomyositis, systemic lupus erythematosus, systemic sclerosis, myasthenia gravis, pemphigus vulgaris, clinical trials, FDA approval, biotechnology, cell therapy, manufacturing, going concern, Nasdaq